Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Whyalla Steelworks sale enters final bidding round

Researchers turn captured carbon dioxide into valuable chemicals

Queensland launches tender for additional gas‍-‍fired generation

WA calls for expressions of interest to build defence manufacturing hub

Corvus Technology opens Victorian manufacturing facility

How better people management systems can help aged care organisations thrive

Outdated, overused and ineffective — time to end mandatory double-checking?

New Support at Home consumer protection measures announced

Chemical-free cleaning: the future of infection control in health care

Latrobe Regional Health charged after nurse "seriously assaulted" by patient

AIFST26 and foodpro 2026 bring science and industry together

Jet Technologies partners with renewable ink technology business

Dematic celebrates 60 years of Australian innovation

For Food's Sake agrifood event returns in September

New CEO and MD for Pure Foods Tasmania